18F-fluoroerythronitroimidazole radiation dosimetry in cancer studies

Journal of Nuclear Medicine

Volumn 43, Issue 12, 2002, Pages 1674-1680

  Tolvanen, Tuula ^a   Lehtiö, Kaisa ^a   Kulmala, Jarmo ^a   Oikonen, Vesa ^a   Eskola, Olli ^b   Bergman, Jörgen ^b   Minn, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TURKU PET CENTRE   (Finland)

Author keywords

18F fluoroerythronitromidazole; PET; Radiation dose

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; FLUORINE 18; FLUOROERYTHRONITROIMIDAZOLE; IMIDAZOLE DERIVATIVE; MISONIDAZOLE; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ABDOMEN; ARTERIAL BLOOD; ARTICLE; BLADDER; CALCULATION; CANCER PATIENT; CANCER RESEARCH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; FEMALE; HEAD; HUMAN; HYDRATION; IMAGING; MALE; NECK; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION; RADIATION ABSORPTION; RADIATION DOSE; THORAX; URINE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; NEOPLASM; SCINTISCANNING;

FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MISONIDAZOLE; NEOPLASMS; NITROIMIDAZOLES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036882163     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hall EJ. Radiosensitizers and bioreductive drugs. In: Hall EJ. ed. Radiobiology for the Radiologist. Philadelphia, PA: J.B. Lippincott; 1994:165-181.
2. Brown JM. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today. 2000;61:57-162.
3. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 1998;46:229-237.
4. Yang DJ, Wallace S, Cherif A, et al. Development of F- 18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795-800.
5. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-991.
6. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
7. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
8. 18F]FETNIM: A potential marker for PET. J Nucl Med. 2001;42:1397-1404.
9. Graham MM, Peterson LM, Link JM, et al. Fluorine-18- fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38:1631-1636.
10. Howell RW, Wessels BW, Loevinger R. in collaboration with the MIRD Committee. The MIRD perspective 1999. J Nucl Med. 1999;40(suppl):3S-10S.
11. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med. 1994;35:1398-1406.
12. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH. Report of the Task Group on Reference Man. Oxford, U.K.: Pergamon Press; 1974:325-327.
13. Deterding TA, Votaw JR, Wang CK, et al. Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med. 2001;42:376-381.
14. International Commission on Radiological Protection. 1990 Recommendation of the International Commission on Radiological Protection. Publication 60. Oxford, U.K.: Pergamon Press; 1990:4-11.
15. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
16. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med. 2001;42:1653-1655.
17. Stabin MG, Stubbs JB, Watson EE. Dosimetry of swallowed non-absorbed technetium 99m radiopharmaceuticals in paediatric patients. Eur J Nucl Med. 1991;18:288-292.
18. Johansson L, Mattsson S, Nosslin B, Leide-Svegbom S. Effective dose from radiopharmaceuticals. Eur J Nucl Med. 1992;19:933-938.
19. 18F]fluoro-2-deoxy-D-glucose in adult humans. J Nucl Med. 1991;32:707-712.
20. 18F-FDG. J Nucl Med. 2002;43:210-214.